6 results about "Related disorder" patented technology

This invention relates to the field of pharmaceutical technology, and discovers that the natural products boldinine and norboldinine can be used as NTSR1 (Neurotensin receptor-1, NTSR1) receptor antagonists and their applications. The compounds are boldinine and norboldinine ((+)-Laurolitsine), which have NTSR1 receptor antagonistic activity and are NTSR1 receptor antagonists that can prevent and treat alcohol poisoning, addiction, schizophrenia, autism spectrum disorder, and mood disorders. Accordingly, this invention can provide novel NTSR1 receptor antagonist prospective compounds with clear targets for the above-mentioned related diseases.

The application discloses application of PTN in preparation of products for treating cognitive impairment caused by severe infection. The inhibitor of PTN provided by the application can inhibit chronic neuroinflammation, thereby preventing and inhibiting formation and development of late cognitive impairment caused by severe infection, and meanwhile, inhibition of expression or function of PTN can effectively block damage of infiltrating macrophages to microglia cells, thereby providing a new direction for treatment of related diseases.

The application discloses application of a TPP2 mutant zebrafish in an ASD neurodevelopment-related disease model and belongs to the technical field of biological medicines. It is found for the first time that a TPP2 gene deletion type zebrafish has the following phenotypes: developmental retardation, developmental deformity, abnormal motor function, social dysfunction, stereotyped behavior, anxiety-like behavior and the like, has the core characteristics of ASD-related neurodevelopment-related diseases and can be used as an animal model for researching ASD neurodevelopment-related diseases, thereby providing an effective approach for diagnosing or treating ASD neurodevelopment-related diseases.

To provide a magnesium-containing oxytocin preparation and a method of use. [Solution] Disclosed are methods and compositions for the treatment of autism spectrum disorder, related disorders, and symptoms of such disorders, comprising the simultaneous administration of oxytocin peptide and magnesium ions. The simultaneous administration of oxytocin peptide and magnesium ions results in a synergistic or enhanced effect on reducing social and communication deficits in patients with autism spectrum disorder. The present invention may address the need for oxytocin peptide formulations that can provide a more pronounced effect on the oxytocin treatment response in people with autism spectrum disorder and related disorders, which exhibit a wide range of variability.

This invention is in the field of medicine. More particularly the invention is in the field of treating sepsis and related disorders, and disorder wherein certain cytokines are elevated. The invention further relates to treating diseases where cytokines need to be suppressed. Further described is a companion diagnostic test.

A compound of formula (I), for use in the treatment of non-traumatic acquired brain injury,in which M represents a NR1R2 group, an OR1 group or a SR1 group, A represents a NR4R5 group, an OR10 group or a hydrogen atom, R3 is a (C1-C6)alkyl group, a (C1-C6)cycloalkyl group, an aryl group, a —CH2-aryl group, a CH2-(C1-C6)cycloalkyl group or a —CH2-heteroaryl group, and its addition salts with pharmaceutically acceptable acids. A compound of formula (I) wherein R5 is a (C1-C8)alkyl group or a (C1-C6)cycloalkyl group, said alkyl and cycloalkyl group being substituted with one, two or three —OCORa group(s).